Articles
OptiNose: Growing Sales Make The Current Market Cap Look Very Low
Sun, Jul. 18 OPTN6 Comments
Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build
Tue, Jul. 13 HRMY1 Comment
The Xeris-Strongbridge Merger Should Create Substantial Value For Shareholders
Tue, Jun. 29 SBBP, XERS11 Comments
Zogenix's Current Price Seems Disconnected From A Strong Fintepla Launch
Wed, Jun. 23 ZGNX9 Comments
Updated OpRegen Data Looks Promising For Lineage
Fri, Jun. 11 LCTX20 Comments
An Updated Look At Glaukos
Sun, Jun. 6 GKOS
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
Thu, May 13 OCUP6 Comments
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
Fri, May 7 SESN48 Comments
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Tue, Apr. 27 PRTK29 Comments
Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Tue, Apr. 20 FREQ4 Comments
Phathom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Wed, Apr. 7 PHAT5 Comments
Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
Wed, Mar. 24 AUPH53 Comments
Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential Reward
Tue, Mar. 16 ALDX9 Comments
Yumanity: Speculative Upside Potential In Advance Of Multiple Near-Term Catalysts
Wed, Mar. 10 YMTX2 Comments
Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders
Mon, Mar. 1 URGN10 Comments
Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space
Wed, Feb. 17 DRNA13 Comments
PAVmed's Esophageal Diagnostic Tools Should Create Strong Shareholder Value
Tue, Feb. 9 PAVM36 Comments
Marketplace Contributors 2021 Top Ideas - Part 2
Tue, Feb. 2 ABUS, AMT, AVHHL29 Comments
Rigel Still Looks Modestly Undervalued Despite The Recent Rally
Mon, Jan. 25 RIGL24 Comments
G1 Therapeutics Likely Still Has Long-Term Upside Ahead Of The Trilaciclib PDUFA Date
Mon, Jan. 18 GTHX45 Comments
2021 Roundtable: General Outlook - Biotech And Healthcare Investing
Mon, Jan. 11 ETNB, KPTI, MRTX3 Comments
Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Thu, Jan. 7 PRVB23 Comments
BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
Dec. 27, 2020 BTAI10 Comments
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec. 22, 2020 KALA15 Comments
Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval
Dec. 19, 2020 XAIR12 Comments
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market
Dec. 7, 2020 CHMA16 Comments
Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
Nov. 30, 2020 EIGR15 Comments
A Look Inside Unity Biotechnology's Transition To An Ophthalmology Company
Nov. 27, 2020 UBX10 Comments
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov. 23, 2020 SVRA7 Comments
Karyopharm Is Extremely Cheap After Recent Sell-Off
Nov. 16, 2020 KPTI41 Comments
Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off
Nov. 12, 2020 ZGNX2 Comments
Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov. 9, 2020 FREQ13 Comments